FDA Approves Pfizer-OPKO's NGENLA™ for Pediatric Growth Hormone Deficiency and Alopecia Areata
TL;DR
Pfizer and OPKO Health have received approval from the U.S. Food and Drug Administration for their treatment for growth hormone deficiency in children. The once-weekly injectable hormone therapy, sold under the brand name Ngenla, will be available in the U.S. in August. The approval lifted Pfizer's shares marginally and Opko Health's nearly 19% in premarket trading. Ngenla will compete with Ascendis Pharma's once-weekly growth hormone injection, Skytrofa, which was approved by the FDA in 2021.
Topics:businesshealthcare#fda-approval#growth-hormone-deficiency#healthcare#ngenla#opko-health#pfizer
- UPDATE 3-Pfizer-OPKO's growth hormone drug gets US approval in kids Yahoo Finance
- FDA approves treatment for teens with severe alopecia The Atlanta Journal Constitution
- Pfizer, Opko gain FDA nod for weekly growth hormone drug Ngenla FiercePharma
- FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency Yahoo Finance
- Pfizer Receives FDA Approval on Alopecia Areata Treatment Litfulo Pharmaceutical Executive
Want the full story? Read the original reporting
Read on Yahoo Finance